Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:public_company
|
| gptkbp:CEO |
gptkb:Brian_Goff
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:CUSIP |
00847X104
|
| gptkbp:focus |
oncology
rare diseases cellular metabolism |
| gptkbp:foundedYear |
2007
|
| gptkbp:hasCompany |
gptkb:Agios_Pharmaceuticals,_Inc.
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
NASDAQ: AGIO
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:ISIN |
US00847X1046
|
| gptkbp:marketCap |
mid-cap
|
| gptkbp:notableProduct |
PYRUKYND (mitapivat)
|
| gptkbp:numberOfEmployees |
~350
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:AGIO
|
| gptkbp:tickerType |
gptkb:stock_market_index
|
| gptkbp:website |
https://www.agios.com/
|
| gptkbp:bfsParent |
gptkb:Agios_Pharmaceuticals,_Inc.
|
| gptkbp:bfsLayer |
7
|